

January 14, 2026

Company name	CellSource Co., Ltd.
Name of representative	Masayuki Yamakawa, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

December 2025 Monthly KPI Fiscal Year Ending October 2026


We are pleased to announce the KPI results for our contract processing services for December 2025, under the fiscal year ending October 2026. Please note that these figures are preliminary and may be subject to revision in quarterly reports or other disclosures.

1. Daily Average Number of Contract Processing Orders




- The daily average number of contract processing orders increased year-on-year to 48.0 orders. The number of contract processing orders for blood-derived products from self-funded orthopedics decreased by 28 orders year-on-year, 42-order increase in contract processing orders for blood-derived products from hybrid orthopedics, 6-order decrease in contract processing orders for blood-derived products from OB&GYN, and 6-order increase in contract processing orders for aesthetic medicine.

2. Monthly Contract Processing Orders for Blood-derived Products by Department



- In December 2025, the number of contract processing orders for blood-derived products by department was as follows: 708 orders for self-funded orthopedics, representing a 3.8% decrease year-on-year, and 586 orders for hybrid orthopedics, an increase of 7.7% year-on-year.
- For self-funded orthopedics, we have continued to strengthen the organizational structure of the medical corporation through business support services enhanced in last fiscal year, although the number of orders has recently decreased.
- For hybrid orthopedics, the number of contract processing orders increased year-on-year due to the implementation of measures targeting key medical institutions.
- Orders for OB&GYN showed slight decrease, and aesthetic medicine showed an upward trend year-on year.

3. Change in Blood-Derived Product Processing Orders from Hybrid Clinics



- While the scope of priority medical institutions was limited in the previous fiscal year to focus management resources, we have redefined and expanded the scope of priority targets in the current fiscal year. This approach aims to balance the maintenance of a stable revenue base with medium to long-term growth.
- "Group 1" represents the core client base that forms the foundation of the company's sales, where the company aims for a stable increase in order volume by continuously allocating a certain amount of sales resources. On the other hand, "Group 2" primarily consists of other medical institutions and newly partnered medical institutions, and is positioned as a group aiming to expand order volume by supporting the launch of new partner clinics and promoting service utilization.
- Consequently, the total order volume for the period reached 1,230 orders, remaining at the same level as the corresponding period of the previous year.
- Group 1, in which we seek to increase order volume by allocating a certain amount of sales resources, saw a year-on-year decrease of 115 orders (0.4 orders per clinic). This was due to some orders being moved forward into October as a result of specific measures. We will continue to pursue a steady buildup of orders through ongoing follow-up and proposal activities for existing priority medical institutions.
- Group 2, which seeks to strengthen order volume by focusing on newly partnered medical institutions, saw a year-on-year increase of 115 orders (0.1 orders per clinic), as the strategy implemented last fiscal year continues to yield positive results.

CellSource Co., Ltd.

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in accordance with the Act on the Safety of Regenerative Medicine, it has handled over 120,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Homepage: <https://www.cellsource.co.jp/en/>
IR Library : <https://www.cellsource.co.jp/en/ir/documents/>
Official note : <https://note.cellsource.co.jp/> (in Japanese)
IR Inquiries : https://www.cellsource.co.jp/contact/index_ir.html

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.
In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*